{
  "symbol": "MNOV",
  "company_name": "Medicinova Inc",
  "ir_website": "https://investors.medicinova.com/",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Press Release Title Example",
          "url": "https://investors.medicinova.com/press-releases",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[![MediciNova, Inc. MediciNova is a biopharmaceutical company that is developing novel therapeutics with a primary focus on neurology and respiratory diseases with unmet medical needs.](https://www.medicinova.com/wp-content/themes/MediciNova/images/logo-MediciNova-170.png)](https://www.medicinova.com/)\n\n  * [Japanese Site 日本語![](https://www.medicinova.com/wp-content/themes/MediciNova/images/flag-japan.png)](http://www.medicinova.jp/)\n  * Search the site...\n\n\n\n\n# Investor Relations\n\n## Press Releases\n\n#  Press Releases \n\n## Keyword Search\n\nNews Category Financial\n\nYear None20242023202220212020201920182017201620152014\n\n2024\n\nDate | Title  \n---|---  \n11/19/24  |  [MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders](/news-releases/news-release-details/medicinova-ceo-yuichi-iwaki-provides-corporate-update-letter) |  [ ![Printer Friendly Version](/sites/g/files/knoqqb29146/themes/site/nir_pid2561/client/images/printer.gif) ](/news-releases/news-release-details/medicinova-ceo-yuichi-iwaki-provides-corporate-update-letter)  \n11/14/24  |  [MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver](/news-releases/news-release-details/medicinova-receives-notice-allowance-united-states-patent-and-0) |  [ ![Printer Friendly Version](/sites/g/files/knoqqb29146/themes/site/nir_pid2561/client/images/printer.gif) ](/news-releases/news-release-details/medicinova-receives-notice-allowance-united-states-patent-and-0)  \n11/11/24  |  [MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis](/news-releases/news-release-details/medicinova-given-notice-monetary-damages-due-under-patent) |  [ ![Printer Friendly Version](/sites/g/files/knoqqb29146/themes/site/nir_pid2561/client/images/printer.gif) ](/news-releases/news-release-details/medicinova-given-notice-monetary-damages-due-under-patent)  \n10/23/24  |  [MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)](/news-releases/news-release-details/medicinova-announces-update-phase-23-clinical-trial-mn-166) |  [ ![Printer Friendly Version](/sites/g/files/knoqqb29146/themes/site/nir_pid2561/client/images/printer.gif) ](/news-releases/news-release-details/medicinova-announces-update-phase-23-clinical-trial-mn-166)  \n09/30/24  |  [MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)](/news-releases/news-release-details/medicinova-support-nih-funded-expanded-access-clinical-trial) |  [ ![Printer Friendly Version](/sites/g/files/knoqqb29146/themes/site/nir_pid2561/client/images/printer.gif) ](/news-releases/news-release-details/medicinova-support-nih-funded-expanded-access-clinical-trial)  \n09/09/24  |  [MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND](/news-releases/news-release-details/medicinova-announces-abstract-regarding-mn-166-ibudilast-combat) |  [ ![Printer Friendly Version](/sites/g/files/knoqqb29146/themes/site/nir_pid2561/client/images/printer.gif) ](/news-releases/news-release-details/medicinova-announces-abstract-regarding-mn-166-ibudilast-combat)  \n09/03/24  |  [MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting](/news-releases/news-release-details/medicinova-announces-acceptance-abstract-regarding-mn-166) |  [ ![Printer Friendly Version](/sites/g/files/knoqqb29146/themes/site/nir_pid2561/client/images/printer.gif) ](/news-releases/news-release-details/medicinova-announces-acceptance-abstract-regarding-mn-166)  \n08/29/24  |  [MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition](/news-releases/news-release-details/medicinova-receives-notice-allowance-united-states-patent-and) |  [ ![Printer Friendly Version](/sites/g/files/knoqqb29146/themes/site/nir_pid2561/client/images/printer.gif) ](/news-releases/news-release-details/medicinova-receives-notice-allowance-united-states-patent-and)  \n06/20/24  |  [MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations](/news-releases/news-release-details/medicinova-chief-business-officer-david-h-crean-phd-assumes) |  [ ![Printer Friendly Version](/sites/g/files/knoqqb29146/themes/site/nir_pid2561/client/images/printer.gif) ](/news-releases/news-release-details/medicinova-chief-business-officer-david-h-crean-phd-assumes)  \n06/05/24  |  [MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer](/news-releases/news-release-details/medicinova-receives-notice-allowance-new-patent-covering-mn-31) |  [ ![Printer Friendly Version](/sites/g/files/knoqqb29146/themes/site/nir_pid2561/client/images/printer.gif) ](/news-releases/news-release-details/medicinova-receives-notice-allowance-new-patent-covering-mn-31)  \n06/03/24  |  [MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024](/news-releases/news-release-details/medicinova-announces-data-phase-1b2a-clinical-trial-mn-166) |  [ ![Printer Friendly Version](/sites/g/files/knoqqb29146/themes/site/nir_pid2561/client/images/printer.gif) ](/news-releases/news-release-details/medicinova-announces-data-phase-1b2a-clinical-trial-mn-166)  \n05/28/24  |  [MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions](/news-releases/news-release-details/medicinova-announces-two-poster-presentations-92nd-eas-congress) |  [ ![Printer Friendly Version](/sites/g/files/knoqqb29146/themes/site/nir_pid2561/client/images/printer.gif) ](/news-releases/news-release-details/medicinova-announces-two-poster-presentations-92nd-eas-congress)  \n05/20/24  |  [MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer](/news-releases/news-release-details/medicinova-receives-notice-allowance-new-patent-covering-mn-30) |  [ ![Printer Friendly Version](/sites/g/files/knoqqb29146/themes/site/nir_pid2561/client/images/printer.gif) ](/news-releases/news-release-details/medicinova-receives-notice-allowance-new-patent-covering-mn-30)  \n05/14/24  |  [MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome](/news-releases/news-release-details/medicinova-receives-notice-allowance-new-patent-covering-mn-29) |  [ ![Printer Friendly Version](/sites/g/files/knoqqb29146/themes/site/nir_pid2561/client/images/printer.gif) ](/news-releases/news-release-details/medicinova-receives-notice-allowance-new-patent-covering-mn-29)  \n05/07/24  |  [MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)](/news-releases/news-release-details/medicinova-receives-issue-notification-new-patent-covering) |  [ ![Printer Friendly Version](/sites/g/files/knoqqb29146/themes/site/nir_pid2561/client/images/printer.gif) ](/news-releases/news-release-details/medicinova-receives-issue-notification-new-patent-covering)  \n04/02/24  |  [MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)](/news-releases/news-release-details/medicinova-announces-abstract-regarding-results-clinical-trial) |  [ ![Printer Friendly Version](/sites/g/files/knoqqb29146/themes/site/nir_pid2561/client/images/printer.gif) ](/news-releases/news-release-details/medicinova-announces-abstract-regarding-results-clinical-trial)  \n03/26/24  |  [MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan](/news-releases/news-release-details/medicinova-receives-notice-allowance-new-patent-covering-mn-28) |  [ ![Printer Friendly Version](/sites/g/files/knoqqb29146/themes/site/nir_pid2561/client/images/printer.gif) ](/news-releases/news-release-details/medicinova-receives-notice-allowance-new-patent-covering-mn-28)  \n03/20/24  |  [MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society](/news-releases/news-release-details/medicinova-announces-two-abstracts-regarding-mn-001-tipelukast) |  [ ![Printer Friendly Version](/sites/g/files/knoqqb29146/themes/site/nir_pid2561/client/images/printer.gif) ](/news-releases/news-release-details/medicinova-announces-two-abstracts-regarding-mn-001-tipelukast)  \n03/12/24  |  [MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology](/news-releases/news-release-details/medicinova-announces-new-data-and-results-mn-166-ibudilast) |  [ ![Printer Friendly Version](/sites/g/files/knoqqb29146/themes/site/nir_pid2561/client/images/printer.gif) ](/news-releases/news-release-details/medicinova-announces-new-data-and-results-mn-166-ibudilast)  \n01/17/24  |  [MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China](/news-releases/news-release-details/medicinova-receives-notice-grant-new-patent-covering-mn-166) |  [ ![Printer Friendly Version](/sites/g/files/knoqqb29146/themes/site/nir_pid2561/client/images/printer.gif) ](/news-releases/news-release-details/medicinova-receives-notice-grant-new-patent-covering-mn-166)\n"
        }
      ]
    },
    {
      "section_name": "Events",
      "links": [
        {
          "title": "Upcoming Events",
          "url": "https://investors.medicinova.com/upcoming-events",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[![MediciNova, Inc. MediciNova is a biopharmaceutical company that is developing novel therapeutics with a primary focus on neurology and respiratory diseases with unmet medical needs.](https://www.medicinova.com/wp-content/themes/MediciNova/images/logo-MediciNova-170.png)](https://www.medicinova.com/)\n\n  * [Japanese Site 日本語![](https://www.medicinova.com/wp-content/themes/MediciNova/images/flag-japan.png)](http://www.medicinova.jp/)\n  * Search the site...\n\n\n\n\n# Investor Relations\n\n## Event Calendar\n\n#  Event Calendar \n\nUpcoming Events \n\nThere are currently no events scheduled. \n"
        }
      ]
    },
    {
      "section_name": "Annual Reports",
      "links": [
        {
          "title": "Annual Report 2024",
          "url": "https://investors.medicinova.com/annual-reports",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[![MediciNova, Inc. MediciNova is a biopharmaceutical company that is developing novel therapeutics with a primary focus on neurology and respiratory diseases with unmet medical needs.](https://www.medicinova.com/wp-content/themes/MediciNova/images/logo-MediciNova-170.png)](https://www.medicinova.com/)\n\n  * [Japanese Site 日本語![](https://www.medicinova.com/wp-content/themes/MediciNova/images/flag-japan.png)](http://www.medicinova.jp/)\n  * Search the site...\n\n\n\n\n# Investor Relations\n\n## Annual Reports\n\n#  Annual Reports \n\n[Filing date ](?field_nir_sec_form_group_target_id%5B471%5D=471&order=field_nir_sec_date_filed&sort=asc \"sort by Filing date\") | [Form](?field_nir_sec_form_group_target_id%5B471%5D=471&order=field_nir_sec_form&sort=asc \"sort by Form\") | View  \n---|---|---  \n04/26/24 | [ARS](/sec-filings/sec-filing/ars/0000950170-24-049171)  \n02/15/24 | [10-K](/sec-filings/sec-filing/10-k/0000950170-24-015920) | [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-k/0000950170-24-015920)  \n04/26/23 | [ARS](/sec-filings/sec-filing/ars/0000950170-23-014827)  \n03/28/23 | [10-K/A](/sec-filings/sec-filing/10-ka/0000950170-23-010297) | [EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT](/sec-filings/sec-filing/10-ka/0000950170-23-010297)  \n02/16/23 | [10-K](/sec-filings/sec-filing/10-k/0000950170-23-003054) | [EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT](/sec-filings/sec-filing/10-k/0000950170-23-003054)  \n02/16/22 | [10-K](/sec-filings/sec-filing/10-k/0001564590-22-005388) | [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-k/0001564590-22-005388)  \n02/19/21 | [10-K](/sec-filings/sec-filing/10-k/0001564590-21-006771) | [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-k/0001564590-21-006771)  \n02/13/20 | [10-K](/sec-filings/sec-filing/10-k/0001564590-20-004605) | [EX-101.INS - XBRL INSTANCE DOCUMENT](/sec-filings/sec-filing/10-k/0001564590-20-004605)  \n02/13/19 | [10-K](/sec-filings/sec-filing/10-k/0001564590-19-002835) | [EX-101.INS - XBRL INSTANCE DOCUMENT](/sec-filings/sec-filing/10-k/0001564590-19-002835)  \n02/13/18 | [10-K](/sec-filings/sec-filing/10-k/0001564590-18-001957) | [EX-101.INS - XBRL INSTANCE DOCUMENT](/sec-filings/sec-filing/10-k/0001564590-18-001957)  \n02/14/17 | [10-K](/sec-filings/sec-filing/10-k/0001564590-17-001547) | [EX-101.INS - XBRL INSTANCE DOCUMENT](/sec-filings/sec-filing/10-k/0001564590-17-001547)  \n02/25/16 | [10-K](/sec-filings/sec-filing/10-k/0001564590-16-013409) | [EX-101.INS - XBRL INSTANCE DOCUMENT](/sec-filings/sec-filing/10-k/0001564590-16-013409)  \n05/05/15 | [ARS](/sec-filings/sec-filing/ars/9999999997-15-009695)  \n03/12/15 | [10-K](/sec-filings/sec-filing/10-k/0001193125-15-089483) | [EX-101.INS - XBRL INSTANCE DOCUMENT](/sec-filings/sec-filing/10-k/0001193125-15-089483)  \n05/02/14 | [ARS](/sec-filings/sec-filing/ars/9999999997-14-009825)  \n03/27/14 | [10-K](/sec-filings/sec-filing/10-k/0001193125-14-118744) | [EX-101.INS - XBRL INSTANCE DOCUMENT](/sec-filings/sec-filing/10-k/0001193125-14-118744)  \n05/03/13 | [ARS](/sec-filings/sec-filing/ars/9999999997-13-009326)  \n03/28/13 | [10-K](/sec-filings/sec-filing/10-k/0001193125-13-132600) | [EX-101.INS - XBRL INSTANCE DOCUMENT](/sec-filings/sec-filing/10-k/0001193125-13-132600)  \n05/03/12 | [ARS](/sec-filings/sec-filing/ars/9999999997-12-009724)  \n03/29/12 | [10-K](/sec-filings/sec-filing/10-k/0001193125-12-137788) | [EX-101.INS - XBRL INSTANCE DOCUMENT](/sec-filings/sec-filing/10-k/0001193125-12-137788)  \n03/31/11 | [10-K](/sec-filings/sec-filing/10-k/0001193125-11-085028)  \n05/06/10 | [ARS](/sec-filings/sec-filing/ars/9999999997-10-011685)  \n03/24/10 | [10-K](/sec-filings/sec-filing/10-k/0001193125-10-065827)  \n05/04/09 | [ARS](/sec-filings/sec-filing/ars/9999999997-09-019140)  \n03/31/09 | [10-K](/sec-filings/sec-filing/10-k/0001193125-09-069548)  \n05/08/08 | [ARS](/sec-filings/sec-filing/ars/9999999997-08-024812)  \n03/17/08 | [10-K](/sec-filings/sec-filing/10-k/0001193125-08-058990)  \n03/14/07 | [ARS](/sec-filings/sec-filing/ars/9999999997-07-012407)  \n02/15/07 | [10-K](/sec-filings/sec-filing/10-k/0001193125-07-033031)  \n02/16/06 | [10-K](/sec-filings/sec-filing/10-k/0001193125-06-033676)  \n06/28/05 | [ARS](/sec-filings/sec-filing/ars/9999999997-05-030175)  \n03/22/05 | [10-K](/sec-filings/sec-filing/10-k/0001193125-05-057087)\n"
        }
      ]
    },
    {
      "section_name": "SEC Filings",
      "links": [
        {
          "title": "SEC Filing Example 2024",
          "url": "https://investors.medicinova.com/sec-filings",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[![MediciNova, Inc. MediciNova is a biopharmaceutical company that is developing novel therapeutics with a primary focus on neurology and respiratory diseases with unmet medical needs.](https://www.medicinova.com/wp-content/themes/MediciNova/images/logo-MediciNova-170.png)](https://www.medicinova.com/)\n\n  * [Japanese Site 日本語![](https://www.medicinova.com/wp-content/themes/MediciNova/images/flag-japan.png)](http://www.medicinova.jp/)\n  * Search the site...\n\n\n\n\n# Investor Relations\n\n## SEC Filings\n\n#  SEC Filings \n\n## SEC Filing Keyword Search\n\nGroup 3,4,5Annual FilingsCurrent ReportsMergers & AcquisitionsOtherProxy FilingsQuarterly FilingsRegistration Statements\n\nFiling year - Any -2024202320222021202020192018201720162015201420132012201120102009200820072006200520042003\n\n- Any -\n\n[Filing date ](?items_per_page=10&order=field_nir_sec_date_filed&sort=asc \"sort by Filing date\") | [Form](?items_per_page=10&order=field_nir_sec_form&sort=asc \"sort by Form\") | [Description](?items_per_page=10&order=field_nir_sec_description&sort=asc \"sort by Description\") | Filing Group | View  \n---|---|---|---|---  \n11/13/24 | [10-Q](/sec-filings/sec-filing/10-q/0000950170-24-126343) | Quarterly report which provides a continuing view of a company's financial position |  Quarterly Filings |  [0000950170-24-126343.rtf](/static-files/21d46163-982e-45e2-8c8f-b84cb86bf9f0) [0000950170-24-126343.xls](/static-files/33df49de-4a3c-4674-bd92-d49f15d689e5) [0000950170-24-126343.pdf](/static-files/4980be0f-264c-4298-bc64-e723d60f72c4) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-q/0000950170-24-126343)  \n08/08/24 | [10-Q](/sec-filings/sec-filing/10-q/0000950170-24-094092) | Quarterly report which provides a continuing view of a company's financial position |  Quarterly Filings |  [0000950170-24-094092.rtf](/static-files/25e636cc-d3e0-406b-b229-14ae56d4e498) [0000950170-24-094092.xls](/static-files/1f9e7d1e-43a4-4aeb-90bf-c1275a47901f) [0000950170-24-094092.pdf](/static-files/2c21cde4-ce53-4919-ada2-2bf98f37e833) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-q/0000950170-24-094092)  \n06/12/24 | [8-K](/sec-filings/sec-filing/8-k/0000950170-24-072461) | Report of unscheduled material events or corporate event |  Current Reports |  [0000950170-24-072461.rtf](/static-files/12764470-33d3-4fd6-8100-99be565f8cee) [0000950170-24-072461.xls](/static-files/11809c3e-18a8-4b82-8527-3adbe2b24b37) [0000950170-24-072461.pdf](/static-files/645498de-5fea-4ae3-9833-432a52f051bf) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0000950170-24-072461)  \n06/12/24 | [4](/sec-filings/sec-filing/4/0001683168-24-004156) | Statement of changes in beneficial ownership of securities |  3,4,5 |  [0001683168-24-004156.rtf](/static-files/f843491d-b612-491d-a2c2-26acf9498ac5) [0001683168-24-004156.xls](/static-files/243b764c-d34c-41ad-b7ff-ca1601d3c725) [0001683168-24-004156.pdf](/static-files/0f9e2b3d-9870-4f3d-99e1-29338276e8bd)  \n06/12/24 | [4](/sec-filings/sec-filing/4/0001683168-24-004154) | Statement of changes in beneficial ownership of securities |  3,4,5 |  [0001683168-24-004154.rtf](/static-files/3e7888b1-3b8e-443a-a8d2-734142f4633e) [0001683168-24-004154.xls](/static-files/d08c86ba-4b8c-4630-8f4e-c68d37a01f6d) [0001683168-24-004154.pdf](/static-files/61e466f9-5aae-4ce9-9d7b-c0adebb9fa49)  \n06/12/24 | [4](/sec-filings/sec-filing/4/0001683168-24-004155) | Statement of changes in beneficial ownership of securities |  3,4,5 |  [0001683168-24-004155.rtf](/static-files/26b66158-e6a3-4649-bcce-6979a88d6c2f) [0001683168-24-004155.xls](/static-files/f45fc562-2808-4965-8518-fbf1ff94e085) [0001683168-24-004155.pdf](/static-files/3191ca83-4677-4274-9bf8-65471320abb4)  \n05/09/24 | [10-Q](/sec-filings/sec-filing/10-q/0000950170-24-056996) | Quarterly report which provides a continuing view of a company's financial position |  Quarterly Filings |  [0000950170-24-056996.rtf](/static-files/914e2a60-5c1b-4bd1-96d2-077b837a55b8) [0000950170-24-056996.xls](/static-files/1ed42f9e-0be7-41d8-b60f-de477ea1865f) [0000950170-24-056996.pdf](/static-files/fbe3d7fc-e1eb-4971-add7-221fdb9376b7) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-q/0000950170-24-056996)  \n04/26/24 | [DEF 14A](/sec-filings/sec-filing/def-14a/0000950170-24-049146) | Official notification to shareholders of matters to be brought to a vote (\"Proxy\") |  Proxy Filings |  [0000950170-24-049146.rtf](/static-files/04dcde60-f0e4-45ea-951a-96089967189e) [0000950170-24-049146.xls](/static-files/c9fe433e-a915-4ea1-913f-8327dad003f5) [0000950170-24-049146.pdf](/static-files/a76d30b0-4da9-4084-b5c5-7c841041d991)  \n04/26/24 | [DEFA14A](/sec-filings/sec-filing/defa14a/0000950170-24-049173) | Additional proxy soliciting materials - definitive |  Proxy Filings |  [0000950170-24-049173.rtf](/static-files/8e32c1bd-fb61-4d1b-8afc-edeae8bbd40a) [0000950170-24-049173.pdf](/static-files/c5ca1f21-5d37-4350-aa27-4067f78e627b)  \n04/26/24 | [ARS](/sec-filings/sec-filing/ars/0000950170-24-049171) | An annual report to security holders |  Annual Filings |  [0000950170-24-049171.rtf](/static-files/fe25ceff-3b5d-4fee-bdab-04b35d379d91) [0000950170-24-049171.pdf](/static-files/b9cdb7d3-6d22-4bfc-965f-bf52af1dffa7)\n"
        }
      ]
    },
    {
      "section_name": "Investor Toolkit",
      "links": [
        {
          "title": "Email Alerts",
          "url": "https://investors.medicinova.com/email-alerts",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[![MediciNova, Inc. MediciNova is a biopharmaceutical company that is developing novel therapeutics with a primary focus on neurology and respiratory diseases with unmet medical needs.](https://www.medicinova.com/wp-content/themes/MediciNova/images/logo-MediciNova-170.png)](https://www.medicinova.com/)\n\n  * [Japanese Site 日本語![](https://www.medicinova.com/wp-content/themes/MediciNova/images/flag-japan.png)](http://www.medicinova.jp/)\n  * Search the site...\n\n\n\n\n# Investor Relations\n\n## Email Alerts\n\n#  Email Alerts \n\nYou may automatically receive Medicinova Inc financial information by email. To choose your options for email notification, please enter your email address below and click Submit.  \n---  \n  \nRequired fields denoted by an asterisk ().\n\nHide lower priority columns\n\nAlert type  \n---  \nMedicinova Inc SEC Alert  \nMedicinova Inc Calendar Alert  \nMedicinova Inc News Alert  \n  \nEmail\n\nLeave this field blank\n"
        }
      ]
    }
  ]
}